Coolbrook Named on the 2025 Global Cleantech 100
15.1.2025 17:01:00 CET | Business Wire | Press release
2025: The Year We Remember the Guardrails Coming Off
Coolbrook, a transformational technology and engineering company, has been named on Cleantech Groups 2025 Global Cleantech 100. This annual list, now in its 16th year, showcases the most promising private cleantech companies making significant contributions to sustainable innovation.
The complimentary report will introduce you to innovators advancing groundbreaking technologies and business models to enable us to act on the ever-increasing climate and environmental crisis.
The cleantech theme is poised for pivotal milestones in 2025 as market forces intensify and innovation accelerates. Continuing trends from 2024, including policy uncertainty, groundbreaking first-of-a-kind (FOAK) projects, and the surging demand for climate adaptation technologies, will emphasize the importance of product and project economics.
Companies that capitalize on organic demand—such as the growing needs of data centers—and prove their technologies in real-world environments without relying on favorable policy support, will find themselves in the best position to succeed. Economic viability will be the defining metric of success in 2025.
"2025 will be remembered as a transformative year for cleantech. The bar has gone up for what kind of level of potential novelty, uniqueness, and cost improvements might be attractive," said Richard Youngman, CEO of Cleantech Group. "The Global Cleantech 100 highlights innovators who are building the foundation for a sustainable and economically viable future."
“Being named in the prestigious 2025 Global Cleantech 100 list is an incredible honor," said Joonas Rauramo, CEO of Coolbrook. “This recognition reflects our steadfast commitment to developing our breakthrough electrification technology that addresses urgent climate challenges. Joining this exceptional group of innovators reinforces our commitment to deliver impactful and economically viable solutions that accelerate heavy industry’s transition to a clean new industrial era.”
Featured companies will be recognized at the Cleantech Forum North America, taking place January 27-29 in San Diego, CA. This event offers participants the opportunity to connect with many of the innovators on the list, along with many other rising stars. The Forum will showcase the latest trends, groundbreaking technologies, and foster collaboration within the cleantech community.
The Global Cleantech 100 program has been running since 2009, the last 12 years with the support of Chubb, the world’s largest property and casualty insurance company.
About Coolbrook:
Hailed as the key technology for industrial decarbonisation globally, Coolbrook is a transformational technology and engineering company on a mission to decarbonise major industrial sectors like petrochemicals and chemicals, iron and steel, and cement. Coolbrook’s revolutionary rotating technology combines space science, turbomachinery and chemical engineering to replace burning of fossil fuels across all major industrial sectors. The technology has two main applications: RotoDynamic Reactor™ (RDR™) to reach 100% CO2 free olefin production, and RotoDynamic Heater™ (RDH™) to provide carbon-free process heating to iron and steel, cement and chemicals production. The RotoDynamic Technology has the potential to reach temperatures of 1700°C and cut 2.4 billion tons (30%) of annual CO2 emissions in heavy industry. For more information, visit www.coolbrook.com.
About Cleantech Group
Cleantech® Group is a research-driven company that helps corporates, public sector, investors and others, identify, assess, and engage with the innovative solutions and opportunities that are related to the world’s massive, and growing, environmental and climate challenges. Our insights and expertise are delivered to clients all over the world through our Research, Consulting, and Events. We have been the leading authority on global cleantech innovation since 2002.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250115529177/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom